(Q36864626)

16 August 2017

1 reference

title

Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia (English)

1 reference

16 August 2017

main subject

Staphylococcus aureus

1 reference

Philip I Hair

1

1 reference

16 August 2017

Susan J Keam

series ordinal

2

1 reference

16 August 2017

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

67

1 reference

16 August 2017

issue

10

1 reference

16 August 2017

page(s)

1483-1512

1 reference

What happened to the streptococci: overview of taxonomic and nomenclature changes

16 August 2017

cites work

1 reference

12 December 2020

In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives

1 reference

12 December 2020

Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry

1 reference

12 December 2020

Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy.

1 reference

12 December 2020

In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes

1 reference

12 December 2020

Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates

1 reference

12 December 2020

Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005)

1 reference

12 December 2020

In vitro susceptibility of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium to daptomycin and other antibiotics

1 reference

12 December 2020

Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004)

1 reference

12 December 2020

Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus

1 reference

12 December 2020

Staphylococcus aureus endocarditis: a consequence of medical progress

1 reference

12 December 2020

Once-daily dosing in dogs optimizes daptomycin safety

1 reference

12 December 2020

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

1 reference

12 December 2020

Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model

1 reference

12 December 2020

Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model

1 reference

12 December 2020

Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis

1 reference

12 December 2020

An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes

1 reference

12 December 2020

Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm

1 reference

12 December 2020

Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus

1 reference

12 December 2020

The treatment triangle for staphylococcal infections

1 reference

12 December 2020

Organizing pneumonia and pulmonary eosinophilic infiltration associated with daptomycin

1 reference

12 December 2020

Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media

1 reference

12 December 2020

Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus

1 reference

12 December 2020

Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.

1 reference

12 December 2020

Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis

1 reference

12 December 2020

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

1 reference

12 December 2020

Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis

1 reference

12 December 2020

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

1 reference

12 December 2020

1 reference

12 December 2020

In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains

1 reference

12 December 2020

Current best practices and guidelines. Assessment and management of complications in infective endocarditis

1 reference

12 December 2020

Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y

1 reference

12 December 2020

Mechanisms of daptomycin resistance in Staphylococcus aureus

1 reference

12 December 2020

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

1 reference

12 December 2020

Complicated infections of skin and skin structures: when the infection is more than skin deep

1 reference

12 December 2020

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis

1 reference

12 December 2020

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

1 reference

12 December 2020

Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

1 reference

12 December 2020

Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance

1 reference

12 December 2020

Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus

1 reference

12 December 2020

Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus

1 reference

12 December 2020

Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves

1 reference

12 December 2020

Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).

1 reference

12 December 2020

Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections

1 reference

12 December 2020

Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection

1 reference

12 December 2020

Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.

1 reference

12 December 2020

Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases

1 reference

12 December 2020

Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar

1 reference

12 December 2020

Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology

1 reference

12 December 2020

Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci

1 reference

12 December 2020

In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp

1 reference

12 December 2020

Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin

1 reference

12 December 2020

In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin

1 reference

12 December 2020

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin

1 reference

12 December 2020

An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus

1 reference

12 December 2020

The many faces of Staphylococcus aureus infection. Recognizing and managing its life-threatening manifestations

1 reference

12 December 2020

Guidelines for the management of intravascular catheter-related infections

1 reference

12 December 2020

In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci

1 reference

12 December 2020

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

1 reference

12 December 2020

Tobramycin and daptomycin disposition when co-administered to healthy volunteers

1 reference

12 December 2020

Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers

1 reference

12 December 2020

Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates

1 reference

12 December 2020

Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001

1 reference

12 December 2020

Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium

1 reference

12 December 2020

In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin

1 reference

12 December 2020

Clinical identifiers of complicated Staphylococcus aureus bacteremia

1 reference

12 December 2020

Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus

1 reference

12 December 2020

Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model

1 reference

12 December 2020

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

1 reference

12 December 2020

Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci

1 reference

12 December 2020

Optimal treatment of complicated skin and skin structure infections

1 reference

12 December 2020

Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections

1 reference

12 December 2020

Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin

1 reference

12 December 2020

Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia

1 reference

12 December 2020

The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects

1 reference

12 December 2020

In vivo pharmacodynamic activity of daptomycin

1 reference

12 December 2020

Development of daptomycin for gram-positive infections

1 reference

12 December 2020

Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy

1 reference

12 December 2020

Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus

1 reference

12 December 2020

Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance

1 reference

12 December 2020

1 reference

12 December 2020

Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline

1 reference

12 December 2020

Resistance studies with daptomycin

1 reference

12 December 2020

Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis

1 reference

12 December 2020

Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus

1 reference

12 December 2020

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects

1 reference

12 December 2020

Clinical practice. Antibiotic allergy

1 reference

12 December 2020

Factors compromising antibiotic activity against biofilms of Staphylococcus epidermidis

1 reference

12 December 2020

Antimicrobial treatment for Intensive Care Unit (ICU) infections including the role of the infectious disease specialist

1 reference

12 December 2020

Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers

1 reference

12 December 2020

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

1 reference

12 December 2020

Effects of vancomycin, teicoplanin, daptomycin and coumermycin on normal immune capabilities

1 reference

12 December 2020

In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains

1 reference

12 December 2020

Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections

1 reference

12 December 2020

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

1 reference

12 December 2020

Antimicrobial susceptibility and staphylococcal chromosomal cassette mec type in community- and hospital-associated methicillin-resistant Staphylococcus aureus

1 reference

12 December 2020

Eosinophilic pneumonia induced by daptomycin

1 reference

12 December 2020

Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents

1 reference

12 December 2020

Staphylococcus aureus bacteremia and endocarditis

1 reference

12 December 2020

Recent advances in the treatment of infections due to resistant Staphylococcus aureus

1 reference

12 December 2020

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

1 reference

12 December 2020

Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin

1 reference

12 December 2020

In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals

1 reference

12 December 2020

In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants

1 reference

12 December 2020

Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species

1 reference

12 December 2020

Surveillance and epidemiology of MRSA bacteraemia in the UK.

1 reference

12 December 2020

Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides.

1 reference

12 December 2020

In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates

1 reference

12 December 2020

The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin

1 reference

12 December 2020

Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey

1 reference

12 December 2020

Moderate liver impairment has no influence on daptomycin pharmacokinetics

1 reference

12 December 2020

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections

1 reference

12 December 2020

EUCAST Technical Note on daptomycin

1 reference

12 December 2020

Daptomycin in vitro susceptibility in European Gram-positive clinical isolates

1 reference

12 December 2020

Linezolid: a review of its use in the management of serious gram-positive infections

1 reference

12 December 2020

Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern

1 reference

12 December 2020

In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections

1 reference

12 December 2020

Evidence of an interaction between nifedipine and nafcillin in humans

1 reference

12 December 2020

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

1 reference

12 December 2020

The importance of in-vitro susceptibility testing in the management of compromised hosts

1 reference

12 December 2020

Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database

1 reference

12 December 2020

Infective endocarditis caused by daptomycin-resistant Enterococcus faecalis: a case report.

1 reference

12 December 2020

Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers

1 reference

12 December 2020

Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections

1 reference

12 December 2020

Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy

1 reference

12 December 2020

Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections

1 reference

12 December 2020

Population pharmacokinetics of daptomycin

1 reference

12 December 2020

Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms

1 reference

12 December 2020

10.2165/00003495-200767100-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1001351421

0 references

1 reference